164 related articles for article (PubMed ID: 26268310)
1. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.
D'Angelo V; Iannotta A; Ramaglia M; Lombardi A; Zarone MR; Desiderio V; Affinita MC; Pecoraro G; Di Martino M; Indolfi P; Casale F; Caraglia M
J Exp Clin Cancer Res; 2015 Aug; 34(1):83. PubMed ID: 26268310
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
3. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
4. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.
Danis E; Yamauchi T; Echanique K; Zhang X; Haladyna JN; Riedel SS; Zhu N; Xie H; Orkin SH; Armstrong SA; Bernt KM; Neff T
Cell Rep; 2016 Mar; 14(8):1953-65. PubMed ID: 26904942
[TBL] [Abstract][Full Text] [Related]
5. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
[TBL] [Abstract][Full Text] [Related]
6. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
[TBL] [Abstract][Full Text] [Related]
7. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
[TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
[TBL] [Abstract][Full Text] [Related]
9. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
10. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
13. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.
Ntziachristos P; Tsirigos A; Van Vlierberghe P; Nedjic J; Trimarchi T; Flaherty MS; Ferres-Marco D; da Ros V; Tang Z; Siegle J; Asp P; Hadler M; Rigo I; De Keersmaecker K; Patel J; Huynh T; Utro F; Poglio S; Samon JB; Paietta E; Racevskis J; Rowe JM; Rabadan R; Levine RL; Brown S; Pflumio F; Dominguez M; Ferrando A; Aifantis I
Nat Med; 2012 Feb; 18(2):298-301. PubMed ID: 22237151
[TBL] [Abstract][Full Text] [Related]
14. Aberrations of EZH2 in cancer.
Chase A; Cross NC
Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
[TBL] [Abstract][Full Text] [Related]
15. Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.
Lee SC; Phipson B; Hyland CD; Leong HS; Allan RS; Lun A; Hilton DJ; Nutt SL; Blewitt ME; Smyth GK; Alexander WS; Majewski IJ
Blood; 2013 Oct; 122(15):2654-63. PubMed ID: 23982173
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
[TBL] [Abstract][Full Text] [Related]
17. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
18. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
Liu YL; Gao X; Jiang Y; Zhang G; Sun ZC; Cui BB; Yang YM
J Cancer Res Clin Oncol; 2015 Apr; 141(4):661-9. PubMed ID: 25326896
[TBL] [Abstract][Full Text] [Related]
20. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
